L
Linda van der Merwe
Researcher at University of Cape Town
Publications - 7
Citations - 784
Linda van der Merwe is an academic researcher from University of Cape Town. The author has contributed to research in topics: Tuberculosis vaccines & Tuberculosis. The author has an hindex of 6, co-authored 7 publications receiving 754 citations. Previous affiliations of Linda van der Merwe include TuBerculosis Vaccine Initiative.
Papers
More filters
Journal ArticleDOI
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults
Brian Abel,Michele Tameris,Nazma Mansoor,Sebastian Gelderbloem,Jane Hughes,Deborah Abrahams,Lebohang Makhethe,Mzwandile Erasmus,Marwou de Kock,Linda van der Merwe,Anthony Hawkridge,Ashley Veldsman,Mark Hatherill,Giulia Schirru,Maria Grazia Pau,Jenny Hendriks,Gerrit Jan Weverling,Jaap Goudsmit,Donata Sizemore,J. Bruce McClain,M.A. Goetz,Jacqueline Gearhart,Hassan Mahomed,Gregory D. Hussey,Jerald C. Sadoff,Willem A. Hanekom +25 more
TL;DR: Vaccination with AERAS-402 is safe and immunogenic in healthy adults, and the immunity induced by the vaccine appears promising: polyfunctional T cells are thought to be important for protection against intracellular pathogens such as Mycobacterium tuberculosis, and evidence is accumulating that CD8(+) T Cells are also important.
Journal ArticleDOI
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
Thomas J. Scriba,Michele Tameris,Nazma Mansoor,Erica Smit,Linda van der Merwe,Fatima Isaacs,Alana Keyser,Sizulu Moyo,Nathaniel Brittain,Alison M. Lawrie,Sebastian Gelderbloem,Ashley Veldsman,Mark Hatherill,Anthony Hawkridge,Adrian V. S. Hill,Gregory D. Hussey,Hassan Mahomed,Helen McShane,Willem A. Hanekom +18 more
TL;DR: It is concluded that in adolescents and children MVA85A safely induces the type of immunity thought to be important in protection against TB, which includes induction of novel Th1‐cell populations that have not been previously described in humans.
Journal ArticleDOI
Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa
Tony Hawkridge,Thomas J. Scriba,Sebastian Gelderbloem,Erica Smit,Michele Tameris,Sizulu Moyo,Trudie Lang,Ashley Veldsman,Mark Hatherill,Linda van der Merwe,Helen A. Fletcher,Hassan Mahomed,Adrian V. S. Hill,Willem A. Hanekom,Gregory D. Hussey,Helen McShane +15 more
TL;DR: The excellent safety profile and quantitative and qualitative immunogenicity data strongly support further trials assessing the efficacy of MVA85A as a boosting vaccine in countries where TB is endemic.
Journal ArticleDOI
A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis–infected Adults
Thomas J. Scriba,Michele Tameris,Erica Smit,Linda van der Merwe,E. Jane Hughes,Blessing Kadira,Katya Mauff,Sizulu Moyo,Nathaniel Brittain,Alison M. Lawrie,Humphrey Mulenga,Marwou de Kock,Lebohang Makhethe,Esme Janse van Rensburg,Sebastian Gelderbloem,Ashley Veldsman,Mark Hatherill,H. Geldenhuys,Adrian V. S. Hill,Anthony Hawkridge,Gregory D. Hussey,Willem A. Hanekom,Helen McShane,Hassan Mahomed +23 more
TL;DR: MVA85A was safe and immunogenic in persons with HIV and/or M.tb- and-or HIV-infected persons in a setting where TB and HIV are endemic and further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations is supported.
Journal ArticleDOI
Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants
Thomas J. Scriba,Michele Tameris,Nazma Mansoor,Erica Smit,Linda van der Merwe,Katya Mauff,E. Jane Hughes,Sizulu Moyo,Nathaniel Brittain,Alison M. Lawrie,Humphrey Mulenga,Marwou de Kock,Sebastian Gelderbloem,Ashley Veldsman,Mark Hatherill,H. Geldenhuys,Adrian V. S. Hill,Gregory D. Hussey,Hassan Mahomed,Willem A. Hanekom,Helen McShane +20 more
TL;DR: The safety of and characterized the T cell response induced by 3 doses of the candidate vaccine, MVA85A, in BCG-vaccinated infants from a setting where tuberculosis is endemic, and data support efficacy evaluation of MVA 85A to prevent tuberculosis in infancy.